Cambridge Cognition Holdings Plc Stock

Cambridge Cognition Holdings plc is a United Kingdom-based company, which is engaged in developing and marketing digital solutions to assess brain health, principally in the United Kingdom, the United States and Europe. Its products include CANTAB, Electronic Clinical Outcomes Assessment (eCOA), NeuroVocalix, Winterlight, Cognition Kit, Clinpal, eConsent, and AQUA. CANTAB Connect gives the control to manage and deliver battery of touchscreen and voice assessments, as well as fully customizable electronic questionnaires and scales. The Company’s therapeutic areas include attention deficit hyperactivity disorder (ADHD), Alzheimer’s Disease, Autism Spectrum Disorder, Cognitive Safety, Core Cognitive Function, Depression, Down’s Syndrome, Drug Abuse Liability, Epilepsy, Huntington’s Disease, Multiple Sclerosis, Neuromuscular Disorders, Obsessive Compulsive Disorder, Parkinson’s Disease, Schizophrenia, Stroke and Cerebrovascular Disease, and Traumatic Brain Injury.